Patient handout

Dyslipidemia / lipid management

PRODUCTION

1. Your condition

This handout is for dyslipidemia / lipid management. Your care team identified this based on: ldl-c above target for risk class acc/aha 2018 grundy.

Other reasons your team may use this plan: lp(a) ≥50 mg/dl (≥125 nmol/l) — universal screen acc/aha 2018; established ascvd — secondary prevention acc/aha 2018; familial hypercholesterolemia / ldl ≥190 / hofh acc/aha 2018 grundy.

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
atorvastatin	40–80 mg	PO	once daily	High-intensity LDL −49 to −55%; LDL nadir 2–4 wk, full effect ~4–6 wk. CTT per-1 mmol/L MACE RR 0.78 (0.76–0.80, PMID 21067804); 4S all-cause death RR 0.70 (0.58–0.85, PMID 7968073); 2026 ACC/AHA Class I
rosuvastatin	20–40 mg	PO	once daily	High-intensity LDL −52 to −63%; nadir 2–4 wk. JUPITER primary-prevention HR 0.56 (0.46–0.69, PMID 18997196); HPS risk-driven 24% RRR (19–28, PMID 12114036)

Plan: 2026 ACC/AHA Dyslipidemia — risk-tier stepwise to LDL goal (absorbs 2022 ACC ECDP non-statin sequence)

3. When to call your provider

Contact your care team if any of the following happen:

New ASCVD event → re-stratify as very-high-risk → LDL <55 target ESC/EAS 2019
Statin intolerance verified by re-challenge → switch class or bempedoic acid CLEAR Nissen 2023
Severe TG (≥1000) → fibrate + diet + alcohol abstinence + APOC3-targeted therapy referral ESC/EAS 2019

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

TG ≥1000 mg/dL — chylomicronemia syndrome / pancreatitis risk (ESC/EAS 2019)
LDL ≥190 untreated OR clinical FH (DLCN ≥6) OR genetic LDLR/APOB/PCSK9 variant (ACC/AHA 2018)
New ASCVD event on max-tolerated statin (ACC 2022)
CK >10x ULN with muscle symptoms +/- renal injury (ACC/AHA 2018)(life-threatening)

5. Follow-up

Cascade screen for FH; vaccinations; ASCVD bundle (BP, A1c, antithrombotic per CCD/STEMI engines) ACC/AHA 2018

6. Sources

Guideline: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Guideline (PMID 41824590 JACC / 41824552 Circulation; retires 2018 blood-cholesterol guideline, absorbs 2022 ACC ECDP non-statin pathway) + ESC/EAS 2019 + ADA SoC 2026